The mid-sized company, Ajanta Pharma ended today’s trading session with a market value of 16,201.44 crore. It is a specialised pharmaceutical company that provides top-notch medicines in more than 30 different countries throughout the world.
Ajanta Pharma said that its net profit stood at Rs 122 crore during Q4FY23 down by 14 per cent YoY from Rs 151 crore during Q4FY22 whereas in FY23 its net profit reached Rs 588 crore as against Rs 713 crore during FY22, representing a fall of 16 per cent.
The company’s operating revenue in Q4FY23 was Rs 882 crore, an increase of 1 per cent year-on-year from Q4FY22’s Rs 870 crore. While its operating revenue in FY23 was Rs 3,743 crore, up 12 per cent YoY from Rs 3,341 crore in FY22.
The company reported that its EBITDA for Q4FY23 was Rs 149 crore, down 17 per cent YoY from Rs 207 crore in Q4FY22 and for FY23 it was Rs 783 crore, down 21 per cent YoY from Rs 929 crore in FY22.
In India, Q4 FY 2023 sales increased by 17 per cent to Rs 287 crore from Rs 245 crore in Q4FY22 and FY 2023 saw sales of Rs 1,174 crore from Rs 982 crore, a 20 per cent growth.
The company said during Q4 FY 2023, R&D expenses were Rs 63 crore up by 7 per cent from (Q4 FY 2022 Rs 59 crore) and in FY23, R&D expenses were Rs 237 crore up by 6 per cent from (12M FY 2022 Rs 204 crore).
Speciality pharmaceutical formulation company Ajanta Pharma conducts institutional business in Africa, branded generic business in India, Asia and Africa, as well as generic business in the US. Many of the business’s products were the first in their particular sub-therapeutic niches to hit the market and have since become market leaders.
The company’s cutting-edge R&D centre is based in Mumbai. The corporation operates 7 excellent production plants in India. Over the past five fiscal years, the company has experienced significant success, with net profit increasing at an 11 per cent CAGR and operating revenue increasing at a 16 per cent CAGR.
